These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 24726804)
1. Design, synthesis, ADME characterization and antileishmanial evaluation of novel substituted quinoline analogs. Gopinath VS; Rao M; Shivahare R; Vishwakarma P; Ghose S; Pradhan A; Hindupur R; Sarma KD; Gupta S; Puri SK; Launay D; Martin D Bioorg Med Chem Lett; 2014 May; 24(9):2046-52. PubMed ID: 24726804 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents. Gopinath VS; Pinjari J; Dere RT; Verma A; Vishwakarma P; Shivahare R; Moger M; Kumar Goud PS; Ramanathan V; Bose P; Rao MV; Gupta S; Puri SK; Launay D; Martin D Eur J Med Chem; 2013 Nov; 69():527-36. PubMed ID: 24095747 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of chalcones as potential antileishmanial agents. Gupta S; Shivahare R; Korthikunta V; Singh R; Gupta S; Tadigoppula N Eur J Med Chem; 2014 Jun; 81():359-66. PubMed ID: 24858541 [TBL] [Abstract][Full Text] [Related]
4. Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials. Vieira NC; Herrenknecht C; Vacus J; Fournet A; Bories C; Figadère B; Espindola LS; Loiseau PM Biomed Pharmacother; 2008 Dec; 62(10):684-9. PubMed ID: 18849137 [TBL] [Abstract][Full Text] [Related]
5. Phase transfer catalyzed synthesis of bis-quinolines: antileishmanial activity in experimental visceral leishmaniasis and in vitro antibacterial evaluation. Palit P; Paira P; Hazra A; Banerjee S; Gupta AD; Dastidar SG; Mondal NB Eur J Med Chem; 2009 Feb; 44(2):845-53. PubMed ID: 18538452 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapy of leishmaniasis. Part XII: design, synthesis and bioevaluation of novel triazole integrated phenyl heteroterpenoids as antileishmanial agents. Suryawanshi SN; Tiwari A; Kumar S; Shivahare R; Mittal M; Kant P; Gupta S Bioorg Med Chem Lett; 2013 May; 23(10):2925-8. PubMed ID: 23582274 [TBL] [Abstract][Full Text] [Related]
7. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. Gupta S; Yardley V; Vishwakarma P; Shivahare R; Sharma B; Launay D; Martin D; Puri SK J Antimicrob Chemother; 2015 Feb; 70(2):518-27. PubMed ID: 25389223 [TBL] [Abstract][Full Text] [Related]
8. Metabolism of 2-substituted quinolines with antileishmanial activity studied in vitro with liver microsomes, hepatocytes and recombinantly expressed enzymes analyzed by LC/MS. Desrivot J; Edlund PO; Svensson R; Baranczewski P; Fournet A; Figadère B; Herrenknecht C Toxicology; 2007 Jun; 235(1-2):27-38. PubMed ID: 17434249 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of ferrocenylquinoline as a potential antileishmanial agent. Yousuf M; Mukherjee D; Pal A; Dey S; Mandal S; Pal C; Adhikari S ChemMedChem; 2015 Mar; 10(3):546-54. PubMed ID: 25619822 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of aryl pyrimidine derivatives as potential leishmanicidal agents. Suryawanshi SN; Kumar S; Shivahare R; Pandey S; Tiwari A; Gupta S Bioorg Med Chem Lett; 2013 Sep; 23(18):5235-8. PubMed ID: 23910597 [TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel quinoline-based thiadiazole, evaluation of their antileishmanial potential and molecular docking studies. Almandil NB; Taha M; Rahim F; Wadood A; Imran S; Alqahtani MA; Bamarouf YA; Ibrahim M; Mosaddik A; Gollapalli M Bioorg Chem; 2019 Apr; 85():109-116. PubMed ID: 30605884 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines. Sunduru N; Nishi ; Palne S; Chauhan PM; Gupta S Eur J Med Chem; 2009 Jun; 44(6):2473-81. PubMed ID: 19217698 [TBL] [Abstract][Full Text] [Related]